The hunt for senolytics trial results that definitively prove drugs can extend human healthspan by clearing "zombie cells" has become one of longevity biology's most watched storylines. A decade after James Kirkland and Tamara Tchkonia's Mayo Clinic team first showed in 2015 that a combination of the cancer drug dasatinib and the plant flavonoid quercetin (D+Q) could selectively kill senescent cells in mice, the clinical pipeline now contains dozens of candidates. But the honest 2026 picture is more nuanced than longevity Twitter often admits: most trials are still Phase 1 or Phase 2, effect sizes in humans are modest, and no senolytic has yet received FDA approval for any aging-related indication.
This article walks through what the trials actually show, which programs are reading out in 2026, and how to think about senolytics as an emerging — not yet proven — class of therapeutics.
What Is a Senolytic?
A senolytic is a drug or compound designed to selectively induce death (apoptosis) in senescent cells — cells that have permanently exited the cell cycle but refuse to die. Instead of undergoing the normal programmed-death pathway, senescent cells secrete a toxic cocktail of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype (SASP).
Cellular senescence is one of the twelve hallmarks of aging. In young tissue, senescent cells are relatively rare and are promptly cleared by the immune system. With age, they accumulate — in adipose tissue, skin, lung, liver, kidney, brain, and joint cartilage — and their SASP drives chronic low-grade inflammation ("inflammaging") that is mechanistically linked to arthritis, fibrosis, metabolic disease, frailty, and neurodegeneration.
The senolytic thesis, first articulated by Kirkland, Tchkonia, and Judith Campisi in the early 2010s, is deceptively simple: if senescent cells drive age-related dysfunction, selectively killing them should reverse that dysfunction. In aged mice, the proof of concept has been striking. In humans, the story is still being written.
The Science: Why Senescent Cells Are Hard to Kill
Senescent cells survive because they upregulate pro-survival pathways — particularly the BCL-2 family of anti-apoptotic proteins (BCL-XL, BCL-W, MCL-1) and tyrosine kinase signaling networks. Senolytic drugs exploit this dependency.
- Dasatinib is an FDA-approved tyrosine kinase inhibitor used in chronic myeloid leukemia. It blocks ephrin-dependent survival signals that senescent preadipocytes rely on.
- Quercetin, a flavonoid found in onions and apples, inhibits PI3K/AKT and BCL-2-family proteins.
- Fisetin, another flavonoid (from strawberries), shows broader senolytic activity in screening assays and is orally bioavailable.
- Navitoclax (ABT-263) is a potent BCL-2/BCL-XL inhibitor developed by AbbVie as a cancer drug — highly effective in killing senescent cells but causes dose-limiting thrombocytopenia (platelet destruction), which has blocked its longevity development.
- UBX-1325 (foselutoclax) is a targeted BCL-XL inhibitor from UNITY Biotechnology designed for intravitreal injection into the eye, avoiding systemic platelet toxicity.
The elegance of the Kirkland approach is using D+Q intermittently — a "hit and run" strategy. Because senescent cells take weeks to re-accumulate, you don't need continuous dosing. A two-day course every few weeks may be sufficient, which dramatically improves the safety profile compared to chronic drug exposure.
The Evidence: What the Trials Actually Show
Let's separate mouse data (compelling) from human data (preliminary).
Mouse studies. Baker et al. (2011, 2016, Nature) used a transgenic mouse (INK-ATTAC) that allowed drug-induced killing of p16-positive senescent cells and showed dramatic extension of healthspan and median lifespan. Xu et al. (2018, Nature Medicine) showed D+Q alleviated physical dysfunction in aged mice and extended post-treatment survival by 36%.
Diabetic kidney disease (Hickson et al. 2019, EBioMedicine). The first human D+Q trial. Nine patients with diabetic kidney disease received three days of oral D+Q. Skin and adipose biopsies showed reduced senescent cell burden and lower SASP cytokines 11 days later. This was a small, open-label, biomarker study — not an efficacy trial — but it demonstrated target engagement in humans.
Idiopathic pulmonary fibrosis (Justice et al. 2019, EBioMedicine). Fourteen IPF patients received intermittent D+Q over three weeks. Physical function improved (6-minute walk, gait speed, chair stands) but pulmonary function did not. Again, small and open-label.
Post-COVID senescence trial (2023). Mayo Clinic and collaborators tested D+Q in patients with persistent post-COVID symptoms on the hypothesis that SARS-CoV-2 induces senescence. Results were mixed — some biomarker improvements without clear symptomatic benefit.
Fisetin at Mayo. The AFFIRM-LITE trial and larger follow-ups are testing fisetin in frail older adults, osteoarthritis, and post-COVID cohorts. As of 2026, data are partially reported: fisetin appears safe but efficacy signals are modest.
UNITY Biotechnology UBX-1325 (BEHOLD and ENVISION). UNITY's lead program targets diabetic macular edema and age-related macular degeneration. The Phase 2 BEHOLD study (reported 2023) showed durable visual acuity improvements from a single intravitreal injection, leading to the Phase 2b ENVISION trial with readouts extending into 2026. This is the most advanced senolytic program with efficacy data in a real disease endpoint.
Oisín Biotechnologies takes a different approach: a lipid nanoparticle delivering a suicide gene construct that is selectively expressed in p16-high or p53-high cells, triggering apoptosis. Preclinical data are promising; first-in-human trials are early.
Current Clinical Status: Who's Working On This
The field has matured from a handful of academic groups into a small industry:
- Mayo Clinic (Kirkland, Tchkonia, LeBrasseur) — still the academic center of gravity, running multiple D+Q and fisetin trials.
- UNITY Biotechnology — publicly traded, focused on ophthalmology after pivoting away from osteoarthritis.
- Oisín Biotechnologies — gene-therapy-style senolytics.
- Cleara Biotech (Netherlands) — FOXO4-DRI peptide that disrupts p53-FOXO4 interaction, selectively killing senescent cells.
- Rubedo Life Sciences — AI-driven discovery of next-generation senolytics with improved selectivity.
- Alkahest (acquired by Grifols) — plasma-fraction approach; young plasma factors that modulate senescent-cell burden and SASP.
- Dorian Therapeutics — small molecules targeting senescence pathways.
Importantly, many of these programs are pursuing specific diseases (diabetic macular edema, osteoarthritis, IPF, frailty) rather than "aging" as an indication. This is a regulatory necessity — the FDA does not recognize aging as a disease — but it also reflects scientific caution. Proving a drug works against a defined pathology is far easier than proving it extends healthspan in healthy adults.
Connection to Gene Editing & Peptides
Senolytics are part of a broader longevity toolkit that increasingly overlaps with gene editing and peptide therapeutics.
- Gene-editing senolytics. Oisín's vector-delivered suicide gene approach is effectively a senolytic gene therapy. Looking further ahead, base editing could in principle install conditional kill switches in cells at risk of senescence, or edit genes like p16INK4a to alter senescence thresholds.
- Peptide senolytics. Cleara's FOXO4-DRI is a peptide senolytic. Other programs are exploring peptides for longevity that modulate senescence biology — including MOTS-c, which protects against metabolic senescence drivers.
- Combination strategies. Several groups are exploring senolytics alongside partial reprogramming (Yamanaka factors) — clearing senescent cells and rejuvenating the rest.
The broader lesson: senolytics are one lever in a multi-lever problem. No single intervention will "solve" aging, and the most effective protocols of the 2030s will likely combine senolytic clearance, partial reprogramming, and metabolic modulation.
Limitations
A rigorous assessment of the senolytics literature highlights several ongoing concerns:
- Small trials. Most human trials enroll 10-30 patients and are open-label. Double-blind, placebo-controlled data are rare.
- Biomarker vs clinical endpoints. Showing reduced p16 expression or lower SASP cytokines in biopsies is not the same as showing patients live longer or function better.
- Senescent-cell heterogeneity. "Senescence" is not one state; senescent fibroblasts, hepatocytes, and immune cells differ in their survival dependencies. No single senolytic hits all subtypes.
- Off-target effects. Dasatinib has real side effects (pleural effusion, cytopenias) from its use in leukemia. Navitoclax causes thrombocytopenia. Fisetin is safer but less potent.
- Immune consequences. Senescent cells may serve transient useful roles (wound healing, tumor suppression). Clearing them systemically could have downsides.
- The replication problem. Many preclinical findings have not been independently reproduced at scale.
As David Sinclair's research and other longevity labs have emphasized, extraordinary claims require extraordinary evidence — and the field is not yet there.
FAQ
Are senolytics FDA-approved?
No. As of 2026, no senolytic has been approved for any indication. Dasatinib is approved for leukemia, not aging. UNITY's UBX-1325 is the most advanced purpose-built senolytic but is still in Phase 2/3 trials for eye disease.
Can I buy D+Q for longevity?
Dasatinib is a prescription chemotherapy drug with real risks and is not legally available for self-experimentation. Quercetin and fisetin are sold as supplements, but supplement-grade purity, dose, and bioavailability vary widely. Self-experimentation is not endorsed by the researchers leading these trials.
What's the difference between senolytics and senomorphics?
Senolytics kill senescent cells. Senomorphics (like rapamycin, metformin, or certain JAK inhibitors) suppress the SASP without killing the cells. Senomorphics are generally safer but require chronic dosing.
Is fisetin better than D+Q?
Unknown. Fisetin has broader activity in some screens and a cleaner safety profile, but human efficacy data are still maturing. The Mayo AFFIRM trials should clarify over 2026-2027.
Why did UNITY abandon osteoarthritis?
UNITY's Phase 2 UBX-0101 knee osteoarthritis trial failed to meet its pain endpoint in 2020. The company refocused on ophthalmology where intravitreal delivery concentrates the drug in target tissue.
Do senolytics affect epigenetic age?
Some small studies have reported modest reductions in epigenetic clock estimates after senolytic treatment, but the data are preliminary and confounded by the clocks' own limitations.
Further Learning
- Hallmarks of Aging Explained — where senescence fits in the bigger picture
- Yamanaka Factors and Partial Reprogramming — a complementary rejuvenation strategy
- David Sinclair's Longevity Research — broader context on aging interventions
